GRACEcast Treatments and Support Video
By cancerGRACE - H. Jack West, MD
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by cancerGRACE - H. Jack West, MD
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 300
Description
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
| Episode | Date |
|---|---|
|
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
|
Jul 31, 2014 |
|
Management of Rare Kidney Tumors
|
Jul 29, 2014 |
|
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
|
Jul 27, 2014 |
|
NanoString Treatment for Kidney Cancer
|
Jul 24, 2014 |
|
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
|
Jul 22, 2014 |
|
How is the Heng Criteria Applied to Kidney Cancer Patients?
|
Jul 20, 2014 |
|
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
|
Jul 17, 2014 |
|
What is PD1 and PDL1 in Kidney Cancer?
|
Jul 15, 2014 |
|
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
|
Jul 13, 2014 |
|
No Clear Answer for Non-Clear Cell Kidney Cancer
|
Jul 10, 2014 |
|
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
|
Jul 08, 2014 |
|
Treating Newly Diagnosed Kidney Cancer
|
Jul 06, 2014 |
|
MET-Amplified Lung Cancer: A New Target for XALKORI?
|
Jul 03, 2014 |
|
The Hottest Thing in Late Stage Kidney Cancer
|
Jul 01, 2014 |
|
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
|
Jun 29, 2014 |
|
The Promise of PD1 Inhibitors in Kidney Cancer
|
Jun 26, 2014 |
|
FGFR and Its Role in Treating Squamous Cell Lung Cancer
|
Jun 25, 2014 |
|
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
|
Jun 24, 2014 |
|
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
|
Jun 23, 2014 |
|
What Is Non-Clear Cell Kidney Cancer?
|
Jun 22, 2014 |
|
Does Gilotrif Help EGFR Positive Lung Cancer Patients?
|
Jun 18, 2014 |
|
The Promise of Immunotherapy in Lung Cancer
|
Jun 18, 2014 |
|
Is Progression-Free Survival Meaningful?
|
Jun 17, 2014 |
|
DDR2 Mutations in Squamous Cell Lung Cancer
|
Jun 16, 2014 |
|
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
|
Jun 12, 2014 |
|
What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
|
Jun 11, 2014 |
|
How Do We Make EGFR Inhibitors Work Better for Patients
|
Jun 09, 2014 |
|
TH 302: New Drug May Make Tumors Less Resistant to Treatment
|
Jun 04, 2014 |
|
Should We Do Broad Sequencing of All Lung Tumors?
|
Jun 01, 2014 |
|
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
|
May 29, 2014 |
|
Why Are Non-Mutated EGFR Genes Called "Wild Type?"
|
May 27, 2014 |
|
Teaching the Immune System to Attack Lung Cancer Tumors
|
May 25, 2014 |
|
Advice for Lung Cancer Patients: Know Thy Cancer
|
May 22, 2014 |
|
Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
|
May 21, 2014 |
|
Treating EGFR Patients After Tarceva Stops Working
|
May 19, 2014 |
|
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?
|
May 15, 2014 |
|
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
|
May 14, 2014 |
|
Targeted Treatment for Lung Cancer After Progression
|
May 13, 2014 |
|
Can Vaccines Fight Lung Cancer?
|
May 12, 2014 |
|
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients
|
May 11, 2014 |
|
Why Do We Call Them "Small Cell Lung Cancer" and "Non-Small Cell Lung Cancer"?
|
May 08, 2014 |
|
Targeting the RAF Pathway in Lung Cancer
|
May 07, 2014 |
|
Is It Possible to Test Lung Tumors Without Doing a Biopsy?
|
May 06, 2014 |
|
What Are PARP Inhibitors, and Might They Improve Outcomes in Small Cell Lung Cancer?
|
May 05, 2014 |
|
New Insights into Small Cell Lung Cancer
|
May 04, 2014 |
|
In What Clinical Setting Should Immunotherapies Be Developed?
|
May 01, 2014 |
|
Maintenance Therapy in Small Cell Lung Cancer
|
Apr 17, 2014 |
|
LDE225 and Small Cell Lung Cancer
|
Apr 17, 2014 |
|
Is There a Silver Bullet for Small Cell Lung Cancer?
|
Apr 17, 2014 |
|
Advice for Newly Diagnosed Small Cell Lung Cancer Patients
|
Apr 17, 2014 |
|
PARP Inhibitors in Small Cell Lung Cancer
|
Apr 17, 2014 |
|
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?
|
Apr 17, 2014 |
|
MK-3475 and its Efficacy in Lung Cancer
|
Apr 17, 2014 |
|
How Do the Different Immune Checkpoint Inhibitors in Lung Cancer Compare?
|
Apr 17, 2014 |
|
Do you see PARP inhibitors as a single drug therapy or more in a combination setting?
|
Apr 17, 2014 |
|
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (video)
|
Apr 16, 2014 |
|
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)
|
Apr 16, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Repeat Biopsies
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Scanning for Progression
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Risk of Flare After Stopping Targeted Therapy
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Can I Pass ALK Onto My Children
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Testing for ALK
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: Xalkori
|
Apr 04, 2014 |
|
ALK Positive Lung Cancer Forum 2014: ALK Rearrangements in Lung Cancer
|
Apr 04, 2014 |
|
Late Stage Oropharynx Cancer, Treatment and Side Effects (video)
|
Mar 30, 2014 |
|
Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)
|
Mar 30, 2014 |
|
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (video)
|
Mar 30, 2014 |
|
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)
|
Mar 30, 2014 |
|
Late Stage Oropharynx Cancer, Introduction and Management (video)
|
Mar 30, 2014 |
|
Late Stage Oropharynx Cancer, Introduction and Management (audio)
|
Mar 30, 2014 |
|
Squamous Lung Cancer Part 5, Q and A Session (video)
|
Dec 20, 2013 |
|
Squamous Lung Cancer Part 5, Q and A Session (audio)
|
Dec 20, 2013 |
|
Squamous Lung Cancer, Part 4: Immunotherapy (video)
|
Dec 10, 2013 |
|
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
|
Dec 10, 2013 |
|
Squamous Lung Cancer, Part 3: Treatment (video)
|
Dec 08, 2013 |
|
Squamous Lung Cancer, Part 3: Treatment (audio)
|
Dec 08, 2013 |
|
Squamous Lung Cancer, Part 2: Genomic Testing (video)
|
Dec 06, 2013 |
|
Squamous Lung Cancer, Part 2: Genomic Testing (audio)
|
Dec 06, 2013 |
|
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (video)
|
Dec 02, 2013 |
|
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)
|
Dec 02, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (video)
|
Sep 28, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)
|
Sep 28, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (video)
|
Sep 28, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)
|
Sep 28, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (video)
|
Sep 21, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)
|
Sep 21, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (video)
|
Sep 19, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)
|
Sep 19, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (video)
|
Sep 09, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)
|
Sep 09, 2013 |
|
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
|
Sep 04, 2013 |
|
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
|
Sep 04, 2013 |
|
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
|
Aug 31, 2013 |
|
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
|
Aug 31, 2013 |
|
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)
|
Aug 26, 2013 |
|
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
|
Aug 26, 2013 |
|
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)
|
Aug 26, 2013 |
|
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
|
Aug 26, 2013 |
|
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)
|
Aug 23, 2013 |
|
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)
|
Aug 23, 2013 |
|
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (video)
|
Aug 23, 2013 |
|
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)
|
Aug 23, 2013 |
|
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)
|
Aug 16, 2013 |
|
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)
|
Aug 16, 2013 |
|
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)
|
Aug 16, 2013 |
|
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
|
Aug 16, 2013 |
|
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (video)
|
Aug 15, 2013 |
|
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)
|
Aug 15, 2013 |
|
Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Aug 15, 2013 |
|
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
|
Aug 15, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (video)
|
Aug 14, 2013 |
|
Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (audio)
|
Aug 14, 2013 |
|
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (video)
|
Aug 14, 2013 |
|
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)
|
Aug 14, 2013 |
|
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (video)
|
Aug 13, 2013 |
|
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)
|
Aug 13, 2013 |
|
ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (video)
|
Aug 11, 2013 |
|
ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)
|
Aug 11, 2013 |
|
ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (video)
|
Aug 07, 2013 |
|
ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)
|
Aug 07, 2013 |
|
Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
Aug 06, 2013 |
|
Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors
|
Aug 06, 2013 |
|
Dr. David Spigel on "Which molecular marker tests do you seek?"
|
Jul 29, 2013 |
|
HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (video)
|
Jul 22, 2013 |
|
HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (audio)
|
Jul 22, 2013 |
|
HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (video)
|
Jul 22, 2013 |
|
HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)
|
Jul 22, 2013 |
|
Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (video)
|
Jul 21, 2013 |
|
Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (audio)
|
Jul 21, 2013 |
|
Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (video)
|
Jul 18, 2013 |
|
Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (audio)
|
Jul 18, 2013 |
|
Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
|
Jul 11, 2013 |
|
Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Jul 11, 2013 |
|
Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
|
Jul 11, 2013 |
|
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
|
Jul 11, 2013 |
|
Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
Jul 11, 2013 |
|
Is there a place for maintenance therapy in extensive stage NSCLC?
|
Jul 04, 2013 |
|
How should we integrate new immunotherapies into treatment strategies for lung cancer?
|
Jul 04, 2013 |
|
How do we approach acquired resistance to targeted therapies in lung cancer?
|
Jul 04, 2013 |
|
What have we learned from the START trial of immunotherapy in locally advanced NSCLC?
|
Jul 04, 2013 |
|
Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
Jul 04, 2013 |
|
Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
|
Jul 04, 2013 |
|
Can we target KRAS effectively in advanced NSCLC?
|
Jul 02, 2013 |
|
Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
|
Jul 02, 2013 |
|
Could BRAF be a new target in NSCLC?
|
Jun 27, 2013 |
|
Are molecular markers just for NSCLC?
|
Jun 21, 2013 |
|
Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Jun 21, 2013 |
|
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
|
Jun 21, 2013 |
|
Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
|
Jun 19, 2013 |
|
Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
|
Jun 19, 2013 |
|
Can we harness our immune system to fight NSCLC?
|
Jun 19, 2013 |
|
Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
|
Jun 19, 2013 |
|
Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
|
Jun 15, 2013 |
|
Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
Jun 15, 2013 |
|
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
|
Jun 15, 2013 |
|
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
|
Jun 13, 2013 |
|
Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
|
Jun 12, 2013 |
|
Can we predict which patients will benefit from Tarceva based on a blood test?
|
Jun 12, 2013 |
|
Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?
|
Jun 11, 2013 |
|
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
|
Jun 10, 2013 |
|
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (video)
|
Jun 09, 2013 |
|
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)
|
Jun 09, 2013 |
|
Is it possible to test for biomarkers in lung cancer on a national scale?
|
Jun 07, 2013 |
|
Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Jun 04, 2013 |
|
Dr. Geoffrey Oxnard: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
Jun 04, 2013 |
|
Dr. Rosalyn Juergens on "My Approach to Maintenance Therapy for Advanced NSCLC"
|
Jun 04, 2013 |
|
Dr. Sarah Goldberg on "Which patients do you send molecular marker testing for?"
|
May 30, 2013 |
|
Dr. Ravi Salgia: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
|
May 30, 2013 |
|
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (video)
|
May 30, 2013 |
|
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)
|
May 30, 2013 |
|
Dr. David Spigel: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
May 28, 2013 |
|
Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
May 28, 2013 |
|
Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?
|
May 24, 2013 |
|
Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
|
May 24, 2013 |
|
Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
May 21, 2013 |
|
Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
May 21, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (video)
|
May 20, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)
|
May 20, 2013 |
|
GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, Canada
|
May 17, 2013 |
|
Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
May 17, 2013 |
|
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
|
May 17, 2013 |
|
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"
|
May 17, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)
|
May 17, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)
|
May 17, 2013 |
|
Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?
|
May 15, 2013 |
|
Dr. Larry Einhorn: Are You Optimistic That a Supercomputer Such as Watson Will Be Able To Improve Cancer Care?
|
May 15, 2013 |
|
Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
May 13, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (video)
|
May 13, 2013 |
|
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)
|
May 13, 2013 |
|
Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
|
May 11, 2013 |
|
Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
May 11, 2013 |
|
Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
May 10, 2013 |
|
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
|
May 10, 2013 |
|
Dr. Greg Riely on "My Approach to Maintenance Therapy for Advanced NSCLC"
|
May 07, 2013 |
|
Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
|
May 07, 2013 |
|
Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (video)
|
May 04, 2013 |
|
Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (audio)
|
May 04, 2013 |
|
Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?
|
May 02, 2013 |
|
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
|
May 02, 2013 |
|
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
May 01, 2013 |
|
Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials
|
May 01, 2013 |
|
Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
|
May 01, 2013 |
|
Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?
|
May 01, 2013 |
|
Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
|
Apr 27, 2013 |
|
Dr. Sarah Goldberg: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
Apr 27, 2013 |
|
Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
|
Apr 27, 2013 |
|
Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
|
Apr 27, 2013 |
|
Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
Apr 26, 2013 |
|
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
Apr 24, 2013 |
|
Dr. Sumanta (Monty) Pal on the Role of Chemotherapy in the Treatment of Kidney Cancer
|
Apr 24, 2013 |
|
Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Apr 18, 2013 |
|
Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
|
Apr 18, 2013 |
|
Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
|
Apr 18, 2013 |
|
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
|
Apr 18, 2013 |
|
Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
Apr 18, 2013 |
|
Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (video)
|
Apr 17, 2013 |
|
Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (audio)
|
Apr 17, 2013 |
|
Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
|
Apr 12, 2013 |
|
Dr. Larry Einhorn on "What Have Been the Most Significant Changes in Cancer Care over the Past Decade or Two?"
|
Apr 12, 2013 |
|
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
|
Apr 12, 2013 |
|
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
|
Apr 12, 2013 |
|
Dr. Greg Riely on Muliplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
|
Apr 11, 2013 |
|
Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
|
Apr 11, 2013 |
|
Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"
|
Apr 10, 2013 |
|
Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
|
Apr 10, 2013 |
|
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (video)
|
Apr 09, 2013 |
|
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (audio)
|
Apr 09, 2013 |
|
Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
|
Apr 08, 2013 |
|
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Apr 08, 2013 |
|
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)
|
Apr 07, 2013 |
|
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)
|
Apr 07, 2013 |
|
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
|
Apr 05, 2013 |
|
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
Apr 05, 2013 |
|
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
|
Apr 03, 2013 |
|
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
|
Apr 03, 2013 |
|
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
|
Mar 31, 2013 |
|
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
|
Mar 31, 2013 |
|
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
|
Mar 30, 2013 |
|
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)
|
Mar 30, 2013 |
|
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)
|
Mar 29, 2013 |
|
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)
|
Mar 29, 2013 |
|
Dr. Matthew Katz: Staging Pancreatic Cancer (video)
|
Mar 29, 2013 |
|
Dr. Matthew Katz: Staging Pancreatic Cancer (audio)
|
Mar 29, 2013 |
|
Dr. Matthew Katz: Introduction to Pancreatic Cancer (video)
|
Mar 29, 2013 |
|
Dr. Matthew Katz: Introduction to Pancreatic Cancer (audio)
|
Mar 29, 2013 |
|
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
|
Mar 29, 2013 |
|
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
|
Mar 29, 2013 |
|
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
|
Mar 25, 2013 |
|
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
|
Mar 25, 2013 |
|
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
|
Mar 25, 2013 |
|
Dr. David Spigel: We've Probably Made Maintenance Therapy More Complicated Than It Needs To Be
|
Mar 25, 2013 |
|
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)
|
Mar 23, 2013 |
|
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
|
Mar 23, 2013 |
|
Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer
|
Mar 21, 2013 |
|
Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
|
Mar 21, 2013 |
|
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
|
Mar 20, 2013 |
|
Dr. William Pao on "How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?"
|
Mar 20, 2013 |
|
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
|
Mar 19, 2013 |
|
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
|
Mar 19, 2013 |
|
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (video)
|
Mar 18, 2013 |
|
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
|
Mar 18, 2013 |
|
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
|
Mar 14, 2013 |
|
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
|
Mar 14, 2013 |
|
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
|
Mar 13, 2013 |
|
Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC
|
Mar 13, 2013 |
|
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
|
Mar 12, 2013 |
|
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)
|
Mar 12, 2013 |
|
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
|
Mar 11, 2013 |
|
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
|
Mar 11, 2013 |
|
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
|
Mar 11, 2013 |
|
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?
|
Mar 10, 2013 |
|
Dr. Monty Pal: Reviewing Bladder Cancer Stages, the Role of Surgery, and the Potential Role of Chemotherapy for Localized Bladder Cancer
|
Mar 07, 2013 |
|
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
|
Mar 07, 2013 |
|
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?
|
Mar 07, 2013 |
|
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
|
Mar 07, 2013 |
|
Dr. Larry Einhorn: Will Costs of Care Limit Our Ability to Deliver Cancer Treatments?
|
Mar 05, 2013 |
|
Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?
|
Mar 05, 2013 |
|
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
|
Mar 05, 2013 |
|
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
|
Mar 04, 2013 |
|
Dr. Greg Riely: How I Use Molecular Marker Information in Earlier Stage NSCLC Patients
|
Mar 04, 2013 |
|
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
|
Mar 04, 2013 |
|
Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy
|
Mar 03, 2013 |
|
Dr. WIlliam Pao on the Goals for Developing MyCancerGenome.org
|
Mar 01, 2013 |
|
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
|
Mar 01, 2013 |
|
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
|
Mar 01, 2013 |
|
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
|
Feb 28, 2013 |
|
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
|
Feb 28, 2013 |
|
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
|
Feb 27, 2013 |
|
Dr. Monty Pal: How Do We Work Up a Kidney Mass That May Be Cancer?
|
Feb 27, 2013 |
|
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn't Enough Tissue for Molecular Testing?
|
Feb 25, 2013 |
|
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
|
Feb 25, 2013 |
|
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
|
Feb 25, 2013 |
|
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?
|
Feb 25, 2013 |
|
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
|
Feb 23, 2013 |
|
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
|
Feb 23, 2013 |
|
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
|
Feb 22, 2013 |
|
What is an Inherited T790M EGFR Mutation, and What Does It Mean?
|
Feb 22, 2013 |
|
What is MyCancerGenome.org?
|
Feb 22, 2013 |